Company intelligence / Profile preview

Kaken Pharmaceutical Co., Ltd.

Bunkyo-ku, Tokyo, Japankaken.co.jp ↗

Ownership: Public · 4521
Employees: ~1143
Development stage: Commercial

Overview

Kaken has multiple commercialized products including Artz (anti-osteoarthritis), Clenafin (onychomycosis treatment), Fiblast Spray (wound-healing), Regroth (periodontal regeneration), Adofeed (pain/inflammation relief), Ebrantil (dysuria/hypertension), Procylin (prostaglandin I2 analog), and Mentax (anti-trichophyton)[3][5]

Therapeutic areas: CardiovascularRheumatologyNephrologyOphthalmologyImmunologyDermatologyOtherNeurologyInfectious Diseases
Modalities: Small moleculesbiologics (recombinant human basic Fibroblast Growth Factor)
Industry: Biotech

Drug pipeline

43 assets

flurbiprofen axetil

Approved

42 more assets in the full pipeline.

Request access →

Partnerships

Alumis Inc. (for TYK2 inhibitor ESK-001 development in Japan)

Beyond the preview

Go deeper on Kaken Pharmaceutical Co., Ltd..

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Kaken Pharmaceutical Co., Ltd..

Explore the full profile